CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
ConclusionIn this retrospective study, patients with ER+/HER2- ABC and IVC/VC treated with CDK4/6i had a significantly better survival compared to those treated with weekly paclitaxel. Further prospective studies that minimise possible selection bias are recommended.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | HER2 | Liver | Study | Urology & Nephrology